In contrast with docetaxel, atezolizumab improved overall survival among patients with locally-advanced or metastatic non-small cell lung cancer (NSCLC) whose disease progressed on or after platinum-based chemotherapy, according to preliminary results from the phase 3 OAK trial.1

For international, open-label, OAK study, investigators randomly assigned 1225 patients to receive either atezolizumab or docetaxel every 3 weeks until disease progression or unacceptable toxicity.

Full results will be submitted for presentation at an upcoming medical meeting in 2016.

A Biologics License Application for atezolizumab in NSCLC was granted Priority Review and action by the U.S. Food and Drug Administration (FDA) is expected by October 19, 2016.

RELATED: Managing PD-1 Inhibitor-induced Pneumonitis

Atezolizumab is already approved for the treatment of patients with locally advanced or metastatic urothelial carcinoma who have disease progression during or following platinum-containing chemotherapy, or have disease progression within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy.                             

Reference

  1. Phase III study showed Genentech’s cancer immunotherapy Tecentriq (atezolizumab) helped people with a specific type of lung cancer live significantly longer compared to chemotherapy [press release]. Genentech website. http://www.gene.com/media/press-releases/14634/2016-08-31/phase-iii-study-showed-genentechs-cancer. Updated August 31, 2016. Accessed September 1, 2016.